FGFR
Fibroblast Growth Factor Receptor family. FGFR2 fusions in cholangiocarcinoma, FGFR3 mutations in bladder cancer. Targeted by pemigatinib, erdafitinib, infigratinib.
No Clinical Trials found for this biomarker.
Fibroblast Growth Factor Receptor family. FGFR2 fusions in cholangiocarcinoma, FGFR3 mutations in bladder cancer. Targeted by pemigatinib, erdafitinib, infigratinib.
No Clinical Trials found for this biomarker.